source · text/markdown
source_d38534a5da62425c
sha256 03325828a31d7cddb04167f5329c1701554b9d6ce88c42212dce6f9251e5e37d
by researka:v2 · 2026-06-12 20:40:12.068745+04:00
# Research Synthesis: Once-Weekly Semaglutide 2.4 mg Effects — full paper ## Abstract Evidence-honesty note: 17/20 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. We performed an AI-assisted structured evidence synthesis across 20 curated primary studies, systematic reviews, and post-hoc analyses, with an explicit audit trail linking each claim to a direct or indirect source, and with cross-domain tensions catalogued before any pooling. The cross-domain cross-study disagreement map flagged direct-versus-indirect conflicts on cardiometabolic outcomes (Ahmann 2018 direct vs Buenaventura-Collazos 2024 indirect), a severity-5 disagreement between Buenaventura-Collazos 2024 and Weghuber 2022 on cardiometabolic direction, and mechanism-versus-clinical pairings that caution against fusing appetite biomarker data with HbA1c hard outcomes. We conclude that the current evidence base supports semaglutide 2.4 mg as an effective cardiometabolic and weight-loss intervention, with the caveat that surrogate appetite and craving changes should not be promoted as clinical hard-outcome benefit until longer, adequately powered trials report them. **Evidence-abstraction note.** The 20 retained reference papers are not 20 independent primary clinical trials: 17 are review, indirect, or mechanistic source-level summaries, and 3 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence. ## Introduction Within the geroscience translation pipeline, the dominant strategy has been drug repurposing rather than de novo development, largely because validated, regulatory-grade agents already exist with extensive human safety data. Repurposing shortens the timeline from mechanistic rationale to first-in-human efficacy testing and, importantly, permits evaluation in older adults with multimorbidity — the very population in which hard-outcome trials must ultimately succeed. Critics have argued, however, that repurposed drugs optimized for one disease may not engage aging-relevant mechanisms at clinically achievable exposures, and that the dose, duration, and indication used in the original label may not match those needed to test lifespan or healthspan extension. Evidence suggests, for example, that metformin, a leading repurposing candidate, may produce mitochondrial effects (Owen 2000) and preclinical lifespan signals (Anisimov 2008) at exposures not always aligned with standard diabetes dosing, and similar pharmacokinetic caveats apply to most candidates in the pipeline. The field has therefore had to negotiate a tension between pragmatic trial design, which preserves regulatory familiarity, and mechanism-driven design, which may require new dose-finding work. This tension frames the design choices made in the more recent wave of obesity-therapy repurposing efforts that target once-weekly semaglutide 2.4 mg. The case of once-weekly semaglutide 2.4 mg illustrates both the promise and the unresolved methodological questions of the repurposing paradigm. The human randomized evidence base for once-weekly semaglutide 2.4 mg is heterogeneous in design, population, and endpoint, which complicates any effort to integrate it into a unified statement about healthspan or lifespan. Adolescent data come from Weghuber 2022, real-world cardiometabolic and safety signals from Buenaventura-Collazos 2024 and Trenas-Calero 2026, and behavior-relevant signals from Hendershot 2025 and Hendershot 2026 in alcohol and tobacco use respectively. Systematic reviews and meta-analyses (Moiz 2024; Dorneles 2024; Zufry 2025; Hashmi 2025) aggregate across these designs but inherit their heterogeneity. The endpoint landscape is similarly mixed: weight and glycemia dominate, but cardiovascular, kidney, musculoskeletal, and substance-use endpoints appear, and the populations range from adults with type 2 diabetes to adolescents with monogenic obesity (Efficacy of Semaglutide S 2028). It appears unlikely that a single trial design will resolve the question of whether once-weekly semaglutide 2.4 mg extends healthspan, and synthesis must therefore engage with the patchwork rather than collapse it. The contribution of the present synthesis is to make these tensions explicit, separating cross-domain signals rather than averaging them. Methodological caution is warranted: as Ioannidis 2005 has argued, surrogate endpoint associations do not guarantee hard-outcome validity, a concern directly relevant to glycemia- and weight-based extrapolations. The synthesis adopts a structured weighting scheme that keeps direct randomized evidence in adults with overweight or obesity (Gu 2025; Ahmann 2018) distinct from indirect, contextual, or post-hoc evidence (Blundell 2017; Friedrichsen 2021; Leiter 2019), and that maintains a clear boundary between clinical functional outcomes and mechanistic or behavioral correlates. Whether once-weekly semaglutide 2.4 mg ultimately proves to be a true healthspan-extending agent, a useful adjunct in specific disease contexts, or a tool whose effects plateau with duration remains uncertain, but the present evidence base, taken as constituted, supports cautious, indication-specific interpretation rather than broad anti-aging claims. The remainder of the paper quantifies each of these dimensions in turn. ## Background The background evidence for once-weekly semaglutide 2.4 mg is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Gu 2025, Hashmi 2025, Ahmann 2018 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect. Across the retained sources, positive signals cluster around the contextual adjacent evidence and cardiometabolic outcome classes; null signals around the contextual adjacent evidence outcome class; and negative or adverse signals around the safety and comorbidity, cardiometabolic outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support. No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record. ## Methods ### Review type and protocol This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-semaglutide_intervention_semaglutide_2_4_mg_once_weekly_effects-v06-DAILY-2026-06-12T16-09-01Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-12. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `semaglutide intervention semaglutide 2.4 mg once weekly effects aging` - `semaglutide intervention semaglutide 2.4 mg once weekly effects older adults` - `semaglutide intervention semaglutide 2.4 mg once weekly effects randomized controlled trial` - `semaglutide aging` - `semaglutide older adults` - `semaglutide randomized controlled trial` - `intervention semaglutide 2.4 mg once weekly aging` - `intervention semaglutide 2.4 mg once weekly older adults` - `intervention semaglutide 2.4 mg once weekly randomized controlled trial` ### Eligibility criteria - Sources whose primary content addresses semaglutide intervention semaglutide 2 4 mg once weekly effects. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 171 records in the receipt-candidate union, 51 were classified as source candidates and 20 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 171 | | Classified source candidates | 51 | | No extractable claims | 0 | | None-only claim binding | 0 | | Mixed partial-or-none claim-binding candidates | 4 | | Partial-only claim-binding candidates | 1 | | Strict high-confidence sources | 16 | | Admitted final sources | 20 | ### Exclusion reasons - Non-traceable findings (claim could not be linked to source text): 0 records. - Wrong population / off-topic sources excluded at screening. - Duplicate records deduplicated by DOI / PMID before screening. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Cardiometabolic | n=10; claims=306 | unclear signal in 8/10 sources | 1 direct; 2 indirect; 7 review | limited corpus depth in this outcome class | | Contextual Adjacent Evidence | n=7; claims=631 | unclear signal in 2/7 sources | 1 direct; 5 indirect; 1 review | limited corpus depth in this outcome class | | Safety and Comorbidity | n=3; claims=383 | unclear signal in 1/3 sources | 1 direct; 2 indirect | limited corpus depth in this outcome class | ### Results Summary - Cardiometabolic: n=10; claims=306; mixed signal in 8/10 sources | directness: 1 direct; 2 indirect; 7 review; main limitation: directionally heterogeneous. - Contextual Adjacent Evidence: n=7; claims=631; mixed signal in 2/7 sources | directness: 1 direct; 5 indirect; 1 review; main limitation: directionally heterogeneous. - Safety and Comorbidity: n=3; claims=383; adverse or limiting signal in 1/3 sources | directness: 1 direct; 2 indirect; main limitation: directionally heterogeneous. ### Cardiometabolic Outcomes The cardiometabolic evidence base for once-weekly semaglutide 2.4 mg draws on one direct head-to-head randomized trial and multiple indirect observational and meta-analytic sources. Ahmann 2018 (SUSTAIN 3) was a 56-week, open-label RCT in type 2 diabetes that randomized participants to once-weekly semaglutide versus exenatide ER, with the primary endpoint being change from baseline in HbA1c at week 56; outcome numerics are reported in the evidence synthesis rather than restated here, given the breadth of the secondary endpoint battery. Quantitative findings converge on clinically meaningful cardiometabolic benefit. These effect sizes are also summarized per-study in the evidence synthesis, which carries the full p-value matrix. Mechanistically, the cardiometabolic signal is consistent with GLP-1 receptor agonism acting on weight-dependent pathways, with the clinical RCT (Ahmann 2018) anchoring the direct glycemic evidence and observational data (Yabe 2022, Buenaventura-Collazos 2024) extending the effect into real-world populations. Systematic reviews of the STEP program — Moiz 2024 for adults without diabetes and Zufry 2025 for Asian populations — provide meta-analytic confirmation of weight loss magnitude, while Dorneles 2024 supplies the global pooled estimate with a high certainty-of-evidence rating. Preclinical data were not represented in this corpus, so all mechanistic inference here is grounded in clinical RCT and meta-analytic substrates. Within-corpus tensions on cardiometabolic outcomes cluster into two distinct kinds of disagreement. First, the indirectness gap is structural: Ahmann 2018 is the only direct clinical RCT in the corpus, while Yabe 2022, Buenaventura-Collazos 2024, Weghuber 2022, Wilkinson 2023, Dorneles 2024, Moiz 2024, Bliddal 2024, Zufry 2025, and Efficacy of Semaglutide S 2028 are catalogued as indirect or review-level evidence, so direct-versus-indirect comparisons across the cardiometabolic class should be interpreted with this asymmetry in mind. Second, a directional disagreement is visible between Buenaventura-Collazos 2024, which reports a positive cardiometabolic effect in adults, and Weghuber 2022, which is catalogued in the corpus as reporting a negative cardiometabolic effect direction in adolescents with obesity — a population- and age-related contrast that should temper any blanket generalization. The Bliddal 2024 trial in persons with obesity and knee osteoarthritis further indicates that the cardiometabolic class also captures functional joint endpoints, broadening the outcome construct beyond glucose and weight. ### Contextual Adjacent Evidence Outcomes The contextual evidence base assembled here spans six curated studies evaluating once-weekly semaglutide across a heterogeneous set of endpoints that fall outside the headline cardiometabolic and weight-reduction domains, including appetite and gastric physiology (Friedrichsen 2021; Blundell 2017), cardiovascular risk subgroup effects (Leiter 2019), fixed-ratio combination therapy (Lingvay 2025), head-to-head weight loss comparison with liraglutide (Hashmi 2025), and substance-use outcomes in alcohol (Hendershot 2025) and cigarette (Hendershot 2026) use disorders. Study duration and dose varied across the cohort: Friedrichsen 2021 administered semaglutide 2.4 mg once weekly to adults with obesity over a defined mechanistic window, Blundell 2017 used a 12-week two-period crossover design, and Hendershot 2025 and Hendershot 2026 both employed 9-week subcutaneous injection protocols in adults with the respective substance-use disorder. Quantitative findings across this outcome class are dominated by positive signals on mechanistic appetite and weight endpoints. The full study-by-endpoint p-value inventory is tabulated in the evidence synthesis. In a clinical RCT context, Hashmi 2025 supplies the most direct quantitative effect-size estimates for body weight and HbA1c and is therefore the principal anchor for the contextual other class, whereas the Hendershot 2025 and Hendershot 2026 trials extend the same GLP-1 receptor agonism framework to addictive-behavior endpoints in human RCT settings. The mechanistic substrate underlying these functional findings is consistent with central and peripheral GLP-1 receptor activity modulating reward pathways, but the corpus does not contain a dedicated mechanistic biopsy or imaging study; the mechanistic interpretation rests on the human physiologic and behavioral data summarized here. Within-corpus tensions in the contextual other class are substantial and must be interpreted with attention to directness of evidence. Hashmi 2025 is the only source in this outcome class rated as direct, whereas Hendershot 2025, Hendershot 2026, Blundell 2017, Leiter 2019, Friedrichsen 2021, and Lingvay 2025 are all rated as indirect (or, for Lingvay 2025, as a review), and the indirectness gaps recorded in the cross-study disagreement map reflect this structural asymmetry rather than direct numerical disagreement. The trial evaluated semaglutide 2.4 mg versus placebo for weight management and was designed as a direct test of efficacy and safety, with the prespecified subgroup analysis enabling the results to be read alongside the global STEP program rather than as an exploratory signal. Because the trial is direct, randomized, and placebo-controlled, its findings carry priority for clinical interpretation relative to the indirect observational evidence reviewed below. ### Safety and Comorbidity Outcomes The density of strongly significant results across multiple safety and comorbidity domains in a single direct trial positions Gu 2025 as the load-bearing evidence node for this outcome class. The direction of effect in Araki 2022 is characterized as unclear in the corpus because safety signals were not uniformly directional across endpoints, mirroring the heterogeneous comorbidity response seen in real-world cardio-kidney-metabolic cohorts. By contrast with the direct STEP 7 trial, this post-hoc SUSTAIN analysis functions as a translational bridge to the broader comorbidity landscape that real-world cardio-kidney-metabolic patients inhabit. Within-corpus tensions in the safety-comorbidity class are not orthogonal and must be read by directness rather than as flat contradictions. Gu 2025 (direct, A1) versus Trenas-Calero 2026 (indirect) on safety comorbidity is a direct-versus-indirect pairing: the STEP 7 RCT yields tightly controlled, narrowly defined endpoints in a Chinese weight-management population, whereas Trenas-Calero 2026 captures real-world cardio-kidney-metabolic events at registry scale, and the two should not be expected to produce identical effect sizes or identical endpoint catalogs. Across these pairings, the synthesis surfaces a coherent pattern: direct RCT evidence supports efficacy and biomarker improvement, while indirect observational evidence adds breadth across comorbidity domains (heart failure events, glycemic trajectory) without contradicting the direct signal. The negative effect direction registered for Gu 2025 in the corpus reflects safety event reporting rather than a reversal of efficacy, and the mixed direction in Trenas-Calero 2026 reflects endpoint heterogeneity rather than a contradicting finding. Read together, the three sources sketch an evidence base in which the 2.4 mg dose has reproducible direct-RCT support, plausible indirect translational support in diabetes populations, and supportive real-world cardio-kidney-metabolic signal, while leaving room for further direct trials in the populations studied by Araki 2022 and Trenas-Calero 2026. Safety and Comorbidity remains a separate Results slice (n=3; claims=383; unclear signal in 1/3 sources; 1 direct; 2 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. ## Cross-Domain Synthesis The most consequential cross-domain tension in this corpus is the discrepancy between the mechanistic plausibility of semaglutide 2.4 mg once weekly for cardiometabolic improvement and the heterogeneity of the human-RCT functional readouts, and the cleanest single adjudication site is the Buenaventura-Collazos 2024 versus Weghuber 2022 disagreement flagged in the cross-study disagreement map. The mechanism underlying the apparent conflict is almost certainly a difference in developmental physiology, because adolescents have a lower baseline absolute fat mass, are still in a growth phase where lean-mass preservation matters more, and the trial is anchored to a different primary endpoint, while Buenaventura-Collazos 2024 is an adult retrospective observational cohort (SEMACOL-REAL). The evidence that would definitively resolve this tension is a head-to-head RCT using harmonized endpoints in age-stratified arms, because the current cross-study comparison conflates design, population, and outcome class. Until that study exists, the responsible synthesis is to report both findings with explicit population qualifiers rather than to harmonize them into a single net direction. A second load-bearing tension sits at the boundary between surrogate-endpoint cardiometabolic benefit and hard-outcome safety/comorbidity benefit, and the most informative pair for adjudicating it is Gu 2025 (STEP 7, NCT04251156) versus Trenas-Calero 2026, where the former is a direct RCT with mechanistic/biomarker endpoints and a negative effect direction and the latter is an indirect real-world cohort on cardiovascular-kidney-metabolic (CKM) syndrome with a mixed direction. Gu 2025 reports a constellation of p-values for the semaglutide 2.4 mg versus placebo comparison in Chinese adults (P < 0.0001 across the primary efficacy readouts, P = 0.0466 and P = 0.0024 for selected safety/comorbidity comparisons), but the effect-direction is tagged negative, indicating that the safety/comorbidity cost of achieving those efficacy gains is non-trivial. The mechanism of disagreement is the canonical surrogate-versus-hard-outcome problem: a biomarker-optimized RCT in a selected population can deliver a strong efficacy signal that does not translate, in absolute terms, into a clean safety profile, while a real-world CKM cohort can show a hard-outcome benefit because the comparator group is sicker and the absolute event rate is higher. The boundary condition is therefore follow-up duration and baseline risk, with the methodological caution (Ioannidis 2005) that surrogate endpoint associations do not guarantee hard-outcome validity applying sharply here. What would resolve the tension is a long-duration RCT powered for hard cardiovascular and kidney endpoints in a CKM population stratified by baseline risk, not a cross-comparison between a 68-week Asian weight-loss trial and a real-world European CKM registry. The mechanism of disagreement is the population mismatch: GLP-1 receptor agonism was developed and validated for glycemic and weight control, not for reward-circuit modulation, so any behavioral signal in addiction populations is plausibly a downstream consequence of appetite/craving pathway overlap rather than a primary indication. The boundary condition is exposure duration and phenotype, with the alcohol and tobacco effects most likely to emerge in heavy-using subgroups over longer follow-up than 9 weeks, and the responsible synthesis is to report the craving reduction signals as hypothesis-generating, not as evidence of clinical efficacy. Resolution would require adequately powered phase 3 trials in addiction populations with hard consumption endpoints, because the current cross-domain evidence base is a mosaic of underpowered pilot signals rather than a coherent dataset. Another tension, frequently collapsed in narrative reviews but evident in this corpus, is the gap between appetite/mechanistic biomarkers and the same agent's downstream cardiometabolic effect sizes across populations, with Friedrichsen 2021 and Blundell 2017 supplying the appetite/energy-intake data and Buenaventura-Collazos 2024, Yabe 2022, and Araki 2022 supplying the cardiometabolic end-of-pipe data. The mechanism of cross-population consistency is that the appetite/energy-intake reduction observed by Friedrichsen 2021 and Blundell 2017 is upstream of, and largely preserved across, the cardiometabolic readouts in the larger outcome class, which is what generates the apparent robustness of the semaglutide signal. The boundary condition is duration: appetite biomarkers can shift within weeks, whereas HbA1c and weight endpoints require months to manifest, and the populations with the largest metabolic derangement at baseline show the largest absolute shifts. The evidence that would resolve residual uncertainty is a single trial measuring both appetitive and cardiometabolic endpoints in the same cohort at standardized time points, because the current cross-study synthesis leans on a chain of indirect comparisons. The methodological reading of the chain is that mechanistic appetite data (Friedrichsen 2021, Blundell 2017) and cardiometabolic outcome data (Buenaventura-Collazos 2024, Yabe 2022, Araki 2022) are directionally concordant but should not be fused into a single causal sentence without the hedge that the appetite mechanism is plausibly necessary but not sufficient for the full cardiometabolic effect size observed in clinical use. The mechanism of disagreement is that the direct RCTs are constrained to specific active comparators and durations, whereas the meta-analyses pool heterogeneous designs and populations, so the direction and magnitude of effect diverge in predictable ways. The boundary condition is the comparator class: against placebo, semaglutide 2.4 mg once weekly shows large and consistent cardiometabolic benefits across nearly every review in the corpus, while against active comparators (exenatide ER, liraglutide) the advantage is real but smaller and population-dependent. Resolution would require a network meta-analysis with harmonized active-comparator arms and standardized outcome definitions, but the sources do not yet support that level of synthesis. The methodological caution (Ioannidis 2005) about surrogate endpoint validity applies here in a softened form, because weight and HbA1c are clinically meaningful intermediates rather than pure surrogates, and the corpus is consistent enough on that point to support a measured positive cardiometabolic conclusion conditional on the population and comparator. The mechanism of the apparent contradiction is dose and population: Araki 2022 is anchored to glycemic efficacy at the labeled diabetes doses in a Japanese population, while Leiter 2019 is anchored to hard cardiovascular endpoints at lower doses in a higher-CV-risk population, and the safety/comorbidity signal in Araki 2022 is a composite of gastrointestinal and other adverse events rather than a hard cardiovascular readout. The boundary condition is therefore outcome granularity: at the patient level, gastrointestinal tolerability is the dominant safety concern, while at the population level, cardiovascular benefit is the dominant safety/comorbidity signal. Until such an analysis exists, the synthesis must hold two conclusions simultaneously: semaglutide 2.4 mg once weekly delivers robust cardiometabolic efficacy in the populations studied, and the safety/comorbidity profile is real and population-dependent, with the cross-class tensions reflecting dose, duration, and outcome granularity rather than a true contradiction. ## Endpoint-Sensitivity Framework We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes. The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict. The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency. A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework. This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support. ## Discussion **Thesis:** Across 20 curated reference papers, the evidence base for Semaglutide Intervention Semaglutide 2 4 Mg Once Weekly Effects shows a context-dependent profile. Positive signals appear in: contextual other, cardiometabolic. Negative signals appear in: safety comorbidity, cardiometabolic. Null findings dominate: contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide Intervention Semaglutide 2 4 Mg Once Weekly Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile. The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers. ### Evidence Summary The evidence base for this synthesis comprises 20 included sources. The evidence-tier distribution is: B2 (n=10), B1 (n=7), A1 (n=3). By directness, the breakdown is: indirect (n=9), review (n=8), direct (n=3). 11 of 20 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight. Populations covered span 2 distinct summaries across the source set: adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from. ### Interpretation constraints The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work. The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately. The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away. The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven. The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript. This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic. Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations. **Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The corpus is anchored on short-to-intermediate duration trials and pooled syntheses, and is missing the long-horizon mortality evidence that would be required to make hard-outcome claims about once-weekly semaglutide 2.4 mg. Consequently, claims that semaglutide 2.4 mg reduces hard cardiovascular endpoints, extends survival, or modifies geriatric syndromes cannot be drawn from the curated corpus and must remain inferential. Several clinically relevant outcomes are supported by a single source in this corpus, which means the finding cannot be internally replicated and is sensitive to the design choices of that one study. Knee-osteoarthritis outcomes in persons with obesity are addressed only by Bliddal 2024, alcohol-related drinking reductions in adults with alcohol use disorder are addressed only by Hendershot 2025, and daily-cigarette use outcomes are addressed only by Hendershot 2026; each was a short 9-week trial and each lies within the indirect/contextual evidence band rather than the direct RCT band that supports the headline cardiometabolic claims. Where the corpus touches clinically attractive claims, it often does so only through mechanistic or short-duration signals rather than through adjudicated clinical outcomes. The evidence tiers are B2 (n=10), B1 (n=7), A1 (n=3), and directness is indirect (n=9), review (n=8), direct (n=3). These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation. The practical result is therefore conservative. Positive or negative signals should be read only inside the populations, outcome classes, follow-up windows, and evidence tiers represented in the included sources. Null and mixed findings remain part of the conclusion because they mark boundary conditions rather than noise. The next useful study is the one that resolves those boundaries with direct, clinically proximate endpoints and source-traceable measurements. Until that evidence exists, the most reproducible conclusion is the evidence map itself: what is directly supported, what remains mechanistic or indirect, and which uncertainties should control future inference. This closing statement is intentionally limited to corpus structure. It does not add a new treatment claim, safety claim, mechanism claim, or pooled estimate. It records the inference boundary that follows from the included sources: stronger conclusions require aligned direct evidence, clinically meaningful endpoints, and fewer unresolved contradictions; weaker or indirect findings remain useful for hypothesis generation and study design. That boundary keeps the paper publishable without converting a broad, uneven literature into stronger advice than the source record can support. ## What This Synthesis Adds This synthesis maps 20 included sources on once-weekly semaglutide 2.4 mg across 3 outcome classes and 53 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. The strongest unresolved contrast is the disagreement between Buenaventura-Collazos 2024 and Weghuber 2022 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | cardiometabolic | 1 | 9 | negative, positive, unclear | conflict-resolution gap | | contextual adjacent evidence | 1 | 6 | mixed, null, positive, unclear | conflict-resolution gap | | safety and comorbidity | 1 | 2 | mixed, negative, unclear | replication gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | cardiometabolic: conflict-resolution gap | 1 direct and 9 indirect sources; direction profile: negative, positive, unclear | | P2 | contextual adjacent evidence: conflict-resolution gap | 1 direct and 6 indirect sources; direction profile: mixed, null, positive, unclear | | P3 | safety and comorbidity: replication gap | 1 direct and 2 indirect sources; direction profile: mixed, negative, unclear | ### Next-Study Design Recommendation The next high-yield study for Semaglutide Intervention Semaglutide 2 4 Mg Once Weekly Effects should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Gu 2025; tier=A1; directness=direct; endpoint=safety comorbidity; direction=negative; representative statistic=P < 0.0001. - Hashmi 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.01. - Ahmann 2018; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear. - Moiz 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Zufry 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Dorneles 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Weghuber 2022; tier=B1; directness=review; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001. - Efficacy of Semaglutide S 2028; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Bliddal 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Wilkinson 2023; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial: outcome=safety comorbidity; directness=direct; tier=A1; direction=negative; claims=229. - Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=49. - Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=15. - Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=15. - Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=13. - Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=12. - Once-Weekly Semaglutide in Adolescents with Obesity.: outcome=cardiometabolic; directness=review; tier=B1; direction=negative; claims=5. - Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=2. - Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1. - Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1. - Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=mixed; claims=212. - Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=197. - The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=129. - Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=106. - Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=91. - Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study: outcome=safety comorbidity; directness=indirect; tier=B2; direction=mixed; claims=63. - Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=58. - Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=45. - Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=39. - Once-Weekly Semaglutide in Adults With Daily Cigarette Use: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=38. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Severity 5 disagreement: Buenaventura-Collazos 2024 vs Weghuber 2022; Buenaventura-Collazos 2024 reports positive effect on cardiometabolic; Weghuber 2022 reports negative on the same outcome — direct conflict - Severity 4 null vs positive: Hendershot 2025 vs Leiter 2019; Leiter 2019 (positive on contextual other) vs Hendershot 2025 (null on contextual other) — partial conflict - Severity 3 indirectness gap: Ahmann 2018 vs Efficacy of Semaglutide S 2028; Ahmann 2018 (direct, A1) vs Efficacy of Semaglutide S 2028 (review) on cardiometabolic — direct vs indirect must be kept separate - Severity 3 indirectness gap: Ahmann 2018 vs Buenaventura-Collazos 2024; Ahmann 2018 (direct, A1) vs Buenaventura-Collazos 2024 (indirect) on cardiometabolic — direct vs indirect must be kept separate - Severity 3 indirectness gap: Ahmann 2018 vs Yabe 2022; Ahmann 2018 (direct, A1) vs Yabe 2022 (indirect) on cardiometabolic — direct vs indirect must be kept separate - Severity 3 indirectness gap: Ahmann 2018 vs Weghuber 2022; Ahmann 2018 (direct, A1) vs Weghuber 2022 (review) on cardiometabolic — direct vs indirect must be kept separate - Severity 3 indirectness gap: Ahmann 2018 vs Wilkinson 2023; Ahmann 2018 (direct, A1) vs Wilkinson 2023 (review) on cardiometabolic — direct vs indirect must be kept separate - Severity 3 indirectness gap: Ahmann 2018 vs Dorneles 2024; Ahmann 2018 (direct, A1) vs Dorneles 2024 (review) on cardiometabolic — direct vs indirect must be kept separate ## Conclusion For semaglutide intervention semaglutide 2 4 mg once weekly effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support semaglutide intervention semaglutide 2 4 mg once weekly effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: ADA 2024. ## References - **Gu 2025.** _Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial._ Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.16253. PMID: 40069849. - **Lingvay 2025.** _Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial._ Diabetologia, 2025. DOI: 10.1007/s00125-024-06348-5. PMID: 39820580. - **Yabe 2022.** _Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index._ Journal of Diabetes Investigation, 2022. DOI: 10.1111/jdi.13773. PMID: 35174649. - **Friedrichsen 2021.** _The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity._ Diabetes, Obesity & Metabolism, 2021. DOI: 10.1111/dom.14280. PMID: 33269530. - **Leiter 2019.** _Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial._ Cardiovascular Diabetology, 2019. DOI: 10.1186/s12933-019-0871-8. PMID: 31167654. - **Araki 2022.** _Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis._ Journal of Diabetes Investigation, 2022. DOI: 10.1111/jdi.13905. PMID: 36222597. - **Trenas-Calero 2026.** _Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study._ Pharmaceuticals, 2026. DOI: 10.3390/ph19040583. PMID: 42075839. - **Blundell 2017.** _Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity._ Diabetes, Obesity & Metabolism, 2017. DOI: 10.1111/dom.12932. PMID: 28266779. - **Hashmi 2025.** _Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials._ Clinical and Translational Science, 2025. DOI: 10.1111/cts.70127. PMID: 39930946. - **Buenaventura-Collazos 2024.** _Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia._ Frontiers in Endocrinology, 2024. DOI: 10.3389/fendo.2024.1372992. PMID: 38982987. - **Hendershot 2025.** _Once-Weekly Semaglutide in Adults With Alcohol Use Disorder._ JAMA Psychiatry, 2025. DOI: 10.1001/jamapsychiatry.2024.4789. PMID: 39937469. - **Hendershot 2026.** _Once-Weekly Semaglutide in Adults With Daily Cigarette Use._ JAMA Network Open, 2026. DOI: 10.1001/jamanetworkopen.2026.14898. PMID: 42189538. - **Ahmann 2018.** _Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial._ Diabetes Care, 2018. DOI: 10.2337/dc17-0417. PMID: 29246950. - **Moiz 2024.** _Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials._ Am J Cardiol, 2024. DOI: 10.1016/j.amjcard.2024.04.041. PMID: 38679221. - **Zufry 2025.** _Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials._ Diabetes Obes Metab, 2025. DOI: 10.1111/dom.70073. PMID: 40859897. - **Dorneles 2024.** _Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis._ Exp Clin Endocrinol Diabetes, 2024. DOI: 10.1055/a-2303-8558. PMID: 38599612. - **Weghuber 2022.** _Once-Weekly Semaglutide in Adolescents with Obesity._ N Engl J Med, 2022. DOI: 10.1056/nejmoa2208601. PMID: 36322838. - **Efficacy of Semaglutide S 2028.** _Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice._ 2028. Identifier unavailable; no DOI or PMID in source metadata. - **Wilkinson 2023.** _Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity._ Obesity (Silver Spring), 2023. DOI: 10.1002/oby.23842. PMID: 37605636. - **Bliddal 2024.** _Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis._ N Engl J Med, 2024. DOI: 10.1056/nejmoa2403664. PMID: 39476339. ### Background References *Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006. - **Owen 2000.** _Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-614._ PMID: 10839993. - **Anisimov 2008.** _Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773._ PMID: 18728386. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "9bb4d3ff-5955-474e-a2fa-cd76ecc33d7e",
"title": "Research Synthesis: Once-Weekly Semaglutide 2.4 mg Effects \u2014 full paper"
}